From: Wiley Research News A ground-breaking new class of oral drugs for treating breast cancer, known as cyclin-dependent kinase (CDK) inhibitors, are generally well-tolerated, with a manageable toxicity profile for most patients. This is the conclusion of a comprehensive review of toxicities and drug interactions related to this class of drugs, recently published in The Oncologist. The excitement surrounding CDK …
-
-
Missing a Deadline After a Breast Cancer Diagnosis
-
Does Discipline Make A Difference in Getting Breast Cancer?
-
Regrets After a Cancer Diagnosis
-
You Are Not Alone After a Breast Cancer Diagnosis
-
The Past and Future Collide After a Breast Cancer Diagnosis
